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Gene expression alterations related to mania and psychosis in
peripheral blood of patients with a first episode of psychosis
ES Gouvea1,2,8, VK Ota1,3,4,8, C Noto1,2,4, ML Santoro3,4, LM Spindola1,3,4, PN Moretti1,3,4, CM Carvalho1,3,4, G Xavier3,4, AC Rios1,
JR Sato4,5, MAF Hayashi4,6, E Brietzke1,7, A Gadelha1,4, RA Bressan1,4, Q Cordeiro1,2 and SI Belangero1,3,4
Psychotic disorders affect ~ 3% of the general population and are among the most severe forms of mental diseases. In early stages
of psychosis, clinical aspects may be difficult to distinguish from one another. Undifferentiated psychopathology at the first-episode
of psychosis (FEP) highlights the need for biomarkers that can improve and refine differential diagnosis. We investigated gene
expression differences between patients with FEP–schizophrenia spectrum (SCZ; N= 53) or FEP–Mania (BD; N= 16) and healthy
controls (N= 73). We also verified whether gene expression was correlated to severity of psychotic, manic, depressive symptoms
and/or functional impairment. All participants were antipsychotic-naive. After the psychiatric interview, blood samples were
collected and the expression of 12 psychotic-disorder-related genes was evaluated by quantitative PCR. AKT1 and DICER1
expression levels were higher in BD patients compared with that in SCZ patients and healthy controls, suggesting that expression of
these genes is associated more specifically to manic features. Furthermore, MBP and NDEL1 expression levels were higher in SCZ
and BD patients than in healthy controls, indicating that these genes are psychosis related (independent of diagnosis). No
correlation was found between gene expression and severity of symptoms or functional impairment. Our findings suggest that
genes related to neurodevelopment are altered in psychotic disorders, and some might support the differential diagnosis between
schizophrenia and bipolar disorder, with a potential impact on the treatment of these disorders.
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INTRODUCTION
Psychotic disorders, including schizophrenia, bipolar disorder and
schizoaffective disorder, affect ~ 3% of the general population1,2
and represent some of the most severe mental diseases.
Characteristic symptoms include hallucinations, delusional beliefs,
severe mood variations and cognitive impairment. However, during
the early stages of psychosis, the clinical aspects may be difficult to
distinguish from one another. The first-episode psychosis (FEP) is a
critical period given that brain abnormalities and cognitive deficits
are already present and progress faster, and more aggressively in
the first years of the disorder,3 whereas the patients are not affected
yet by factors related to disease progression, that is, duration of
illness and exposure to antipsychotics.4,5
More than a century has passed since Kraepelin first proposed
the distinction between dementia praecox (schizophrenia) and
manic-depressive insanity (bipolar disorder),6 but as both dis-
orders may share the same psychotic symptoms, differentiating
schizophrenia spectrum disorders from bipolar disorder is still a
challenge. Therefore, different lines of research aim to identify
biomarkers capable of distinguishing these disorders, including
studies based on gene expression in peripheral tissues.7 On the
other hand, some genes, including microRNAs, show a concordant
expression and association for both schizophrenia and bipolar
disorder in blood8 and also in brain tissues,9,10 showing a possible
common pathophysiological mechanism between these disorders,
beyond the diagnostic boundaries. Moreover, previous studies
revealed an effect of antipsychotics on gene expression.11–13
Therefore, assessing gene expression in early stages, such as FEP,
is crucial, particularly before the administration of antipsychotics,
but this is only feasible in peripheral tissues.
The majority of studies have focused on schizophrenia-
spectrum psychosis, suggesting alterations in genes related to
myelination, neurodevelopment and AKT pathway,14 although
affective psychoses studies are under-represented in the literature,
particularly early-stage affective psychoses. Very few studies on
gene expression of antipsychotic-naive bipolar disorder patients
have been conducted,15–18 reporting alterations in inflammatory
genes, such as TNF,15 and in genes of AKT1/mTOR pathway.18
Our objectives are to investigate differences in the messenger
RNA (mRNA) levels of 12 genes among individuals with FEP of
schizophrenia-spectrum disorder (SCZ), FEP with mania (BD) and
healthy controls. We also want to verify whether gene expression
is correlated to clinical features, including functional impairment
and severity of psychotic, manic, and depressive symptoms.
Particularly, we compared SCZ with BD to identify diagnostic
specificity (genes related to manic symptoms), and FEP (both SCZ
and BD) and healthy controls to find genes related to psychosis
itself as a broad syndrome.
To our knowledge, this is the first study that compares gene
expression between antipsychotic-naive FEP of schizophrenia
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spectrum disorder and FEP with mania. The study aims are to
differentiate BD and SCZ, improving early diagnosis and adequate
intervention.
We selected the genes based on their biological role in
psychotic disorders. As a second criterion, these genes should
be expressed in whole blood (according to information available
in http://www.genecards.org). We selected genes related to
dopamine neurotransmission (COMT), inflammation and the
immune system (TNF), neurodevelopment (DISC1, PAFAH1B1 and
NDEL1), myelination (MBP), cell signaling (AKT1), the microRNA
machinery (DGCR8, DICER1 and DROSHA), protein degradation
(UFD1L) and adhesion (DGCR2). Some genes were selected mainly
because of their location in the 22q11.2 region (COMT, DGCR2,
DGCR8 and UFD1L), as its deletion is one of the strongest known
genetic risk factors for psychotic disorders.19 We previously analyzed
the same genes in other studies comparing FEP (excluding
individuals with bipolar disorder diagnosis) with ultra-high risk
individuals and controls, with positive findings.11,12,20,21–23 Here a
comparison between FEP of schizophrenia spectrum disorder
(SCZ) and FEP with mania (BD) is presented, as well as between BD
and healthy controls.
MATERIALS AND METHODS
Study population
The Research Ethics Committee of UNIFESP approved the research
protocol, and all participants and family members provided written
informed consent prior to enrollment in the study (CEP 0603/10).
Antipsychotic-naive FEP patients (N= 69) were recruited from a
psychiatric emergency unit in São Paulo, Brazil. The diagnosis of a
psychotic disorder was established by trained psychiatrists based on the
criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fourth
Edition (DSM-IV), using the Structured Clinical Interview of the DSM-IV.
Patients were assessed at baseline and followed up for at least 2 months.
At the end of follow-up, patients with a schizophrenia or schizophreniform
disorder diagnosis were classified as FEP of schizophrenia spectrum
disorder (SCZ, N= 53) and patients who met bipolar disorder (with
psychotic symptoms) diagnostic criteria were classified as FEP with mania
(BD, N= 16).
Inclusion criteria were age between 16 and 40 years and no previous
history of antipsychotic medication. Prior treatment with benzodiazepines
was allowed. Patients with psychotic episodes due to a general medical
condition, substance-induced psychotic disorder, intellectual disability or
psychotic episodes that were associated with major depressive disorder
were excluded.
The patients were assessed by: (a) PANSS (Positive and Negative
Syndrome Scale);24 (b) CGI (Clinical Global Impression Scale);25 (c) GAF
(Global Assessment of Functioning Scale), (d) CDSS (Calgary Depression
Scale for Schizophrenia);26 and (e) YMRS (Young Mania Rating Scale).
PANSS dimensions were derived from a previous study in a Brazilian
population.27
The healthy control group (N= 73) comprised age- and gender-matched
volunteers with no current or previous psychiatric diagnoses or first-degree
family history of psychotic disorders.
Peripheral blood samples were collected prior to the administration of
antipsychotics (for patients) or after psychiatric interview (for controls).
Analysis of transcript levels of selected genes
A total of 5 ml of whole blood was collected in PAXgene RNA tubes
(PreAnalytix, Hombrechtikon, Switzerland). RNA was isolated using a
PAXgene Blood RNA kit (Qiagen, Germantown, MD, USA) according to the
manufacturer’s instructions. RNA integrity was determined through
electrophoresis on a 1.0% agarose gel, and the quality and quantity of
the RNA samples were determined using a NanoDrop ND-1000 spectro-
photometer (Nanodrop, Wilmington, DE, USA).
Approximately 400 ng of each RNA sample was reverse-transcribed
using a High-Capacity cDNA Reverse Transcription Kit (Life Technologies,
Foster City, CA, USA). Then, 20 to 100 ng of complementary DNA
(cDNA) was diluted in H2O, mixed with TaqMan Universal PCR Master
Mix (Life Technologies), and loaded on Taqman Low-Density Array (TLDA)
microfluidic cards (Life Technologies). Probes and primers of 12 target
genes, two housekeeping genes (ACTB and GAPDH), and one positive
control for the reaction (18S) were preloaded in the 384 wells (in triplicates)
of each TLDA card (Life Technologies). Assays and the exons and
transcripts that they recognize are described in Supplementary
Table 1. The experiments were performed in accordance with the
manufacturer's instructions using the ViiA 7 Real-Time PCR System (Life
Technologies).
Genes were selected based on their previously reported association
with psychotic disorders and their expression in blood (http://www.
genecards.org/).
Gene expression was quantified using the relative threshold method
(Crt) with the geometric mean (GM) between ACTB and GAPDH as the
endogenous control. Delta cycle relative threshold values (ΔCrt = Crttarget
gene−CrtGM) were calculated for each sample and 2
-ΔCrt values were
included in the PASW Statistics (version 18.0, SPSS, Chicago, IL, USA)
data set.
Statistical analysis
Sample size was chosen using G*Power 3.1.6 software (Heinrich-Heine-
Universität Düsseldorf, Düsseldorf, Germany) and considering an analysis
of variance test, with medium effect size f= 0.30, α=0.05; power = 0.80 and
Table 1. Clinical and demographic characteristics of the participants
Variable Controls SCZ BD Test value; df; P-value
Gender
Males (%) 42 (57.5) 34 (64.2) 12 (75)
Females (%) 31 (42.5) 19 (35.8) 4 (25) χ2= 1.869; df= 2; P= 0.393
Age in years; mean (s.d.) 25.66 (7.31) 26.34 (7.53) 25.13 (6.98) F(2,139)= 0.220; P= 0.803
PANSS negative; mean (s.d.) 27.32 (10.38) 15.67 (6.80) t= 3.692; df= 60; P= 4.826 × 10-4*
PANSS disorganization/cognition; mean (s.d.) 27.56 (7.91) 29.09 (6.73) t=− 0.640; df= 59; P= 0.524
PANSS excitement; mean (s.d.) 26.42 (10.39) 37.68 (11.17) t=− 2.946; df= 60; P= 0.005*
PANSS positive; mean (s.d.) 35.94 (6.97) 35.18 (7.97) t= 0.433; df= 59; P= 0.666
PANSS depression/anxiety; mean (s.d.) 25.33 (9.29) 24.83 (7.23) t=− 0.066; df= 59; P= 0.948
PANSS total; mean (s.d.) 96.27 (20.09) 91.55 (19.21) t= 0.709; df= 58; P= 0.481
GAF; mean (s.d.) 31.96 (8.81) 20.43 (9.60) t= 3.711; df= 16.957; P= 0.002*
CGI; mean (s.d.) 4.87 (0.74) 5.36 (1.15) t=− 1.183; df= 16.062; P= 0.254
CDSS; mean (s.d.) 4.85 (5.32) 1.00 (1.49) t= 1.416; df= 36; P= 0.165
YMRS; mean (s.d.) 11.63 (10.87) 27.23 (12.12) t=− 4.242; df= 36.088; P= 1.473 × 10-4*
Abbreviations: BD, first-episode of psychosis—mania with psychosis; CDSS, Calgary Depression Scale for Schizophrenia; CGI, Clinical Global Impression Scale;
df, degrees of freedom; GAF, Global Assessment of Functioning Scale; PANSS, Positive and Negative Syndrome Scale; SCZ, first-episode of psychosis—
schizophrenia spectrum; YMRS, Young Mania Rating Scale. *Po0.05.
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3 groups. Two-sided tests were used for statistical analyses. For continuous
variables, normality and homogeneity was checked with Shapiro–Wilk
and Levene tests and log-transformed as needed. Gender and age
differences between the SCZ, BD and control group were verified using the
χ2-test and analysis of variance test, respectively. Differences in severity of
symptoms and functional impairment (CDSS, CGI, GAF and YMRS total
scores and PANSS scores) were compared using Student’s t-test.
2-ΔCrt values were compared among SCZ, BD and control groups using
general linear model (GLM), with gender as a fixed factor if necessary and
with Bonferroni correction for multiple comparisons (12, considering the
number of genes assessed). Post hoc comparisons were carried out using
the Bonferroni test. In addition, for genes that were differentially
expressed, we verified the correlation between the 2-ΔCrt values and the
clinical aspects using linear regression and inserting group (SCZ or BD) as
an independent variable. In order to evaluate the predictive power of these
genes, receiver-operating characteristic curves were obtained, and the
respective statistical significance were assessed by χ2-test on the area
under the curve (AUC). The significance level was set at 5%.
RESULTS
The clinical and demographic characteristics of the participants
are presented in Table 1.
SCZ patients exhibited higher scores on the negative dimension
of the PANSS, and lower scores on the excitement compound of
the PANSS and YMRS, than BD patients (Table 1). In addition, BD
patients presented with poorer global function, as indicated by
GAF (Table 1), compared with SCZ patients. No significant age or
gender differences were observed among the different groups.
Analysis of transcript levels of selected genes among
antipsychotic-naive SCZ, BD patients and healthy controls
Gene expression results comparing the three groups (SCZ, BD and
healthy controls) are reported in Table 2. Four genes were found
to be differentially expressed among the groups after Bonferroni
correction for 12 comparisons. Of them, two genes (MBP and
NDEL1) exhibited higher expression levels in antipsychotic-naive
patients (both SCZ and BD) than in healthy controls (Table 2).
Moreover, the expression of two other genes, AKT1 and DICER, was
higher in BD than in both SCZ patients and controls (Table 2).
The expression of these four genes was not correlated with
prior benzodiazepine administration (P40.05) or age (P40.05).
We analyzed the receiver-operating characteristic curve and
we found the same results: AKT1 and DICER1 2-ΔCrt values
differentiated BD from SCZ patients (AKT1 AUC=0.768, P= 0.001;
DICER1 AUC=0.812, P= 1.706 × 10-4; Supplementary Figure 1) and
healthy controls (AKT1 AUC=0.798, P= 2.129 × 10-4; DICER1 AUC=
0.865, P= 5.525 × 10-6; Supplementary Figure 2), but not SCZ from
healthy controls (AKT1 AUC=0.505, P= 0.927; DICER1 AUC=0.561,
P= 0.246; Supplementary Figure 3). On the other hand, MBP and
NDEL1 ΔCrt values did not distinguish SCZ from BD (MBP
AUC=0.597, P= 0.267; NDEL1 AUC=0.553, P= 0.525; Supplemen-
tary Figure 1), but both could differentiate SCZ (MBP AUC=0.677,
P= 0.006; NDEL1 AUC=0.660, P= 0.002; Supplementary Figure 3)
and BD patients (MBP AUC=0.805, P= 2.856 × 10-4; NDEL1 AUC=
0.728, P= 0.004; Supplementary Figure 2) from healthy controls.
Correlation between gene expression and clinical characteristics
We tested the correlation of differential gene expression (AKT1,
DICER, MBP and NDEL1) and the severity of symptoms and
functional impairment (CDSS, CGI, GAF and YMRS total scores, and
PANSS scores) using linear regression and inserting group as an
independent variable. However, no significant correlation was
detected after Bonferroni correction for multiple comparisons. T
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DISCUSSION
In the present study, we identified gene expression alterations that
might be linked to manic and psychotic features. We primarily
detected that AKT1 and DICER1 expression levels were higher in BD
patients compared with SCZ patients and controls, suggesting that
the expression of these genes is associated more specifically to manic
features. In addition, MBP and NDEL1 expression levels were higher in
both SCZ and BD patients than in healthy controls, indicating that
these genes may be related to psychosis per se (independently of
diagnosis). We described similar results comparing FEP (excluding BD)
and controls in a previous study.22 Here we focused on verifying if
these changes in gene expression are also observed in BD, and
moreover, if they can discriminate BD from SCZ patients. Although all
these four genes have a role in central nervous system, this study
aimed to find potential biomarkers, even if they might not be related
to the pathophysiology of the disease. A brief description of each
comparison (SCZ×BD and BD×control) and the relationship of each
gene with psychotic disorders are described below.
SCZ and BD
Two genes were differentially expressed in BD, when compared
with both SCZ and healthy controls, namely AKT1 (V-Akt Murine
Thymoma Viral Oncogene Homolog 1) and DICER1 (Dicer 1,
ribonuclease type III).
AKT1, which encodes a serine–threonine protein kinase, is
involved in a variety of central nervous system functions such as
neurodevelopment, synaptic plasticity and protein synthesis.28
Moreover, AKT1 was shown to facilitate dopamine signaling,29,30
and to regulate a wide array of cellular processes, such as
metabolism, growth, proliferation and apoptosis.31 AKT1 partici-
pates in the PI3K/Akt/mTOR pathway, which is important for many
immunological mechanisms.32
In addition, lithium, antidepressants, antipsychotics and other
mood stabilizers seem to increase phosphorylation of AKT.33–35 A
decrease in AKT1 protein and mRNA levels was found in
postmortem brain tissue and lymphocyte-derived cells of indivi-
duals with schizophrenia and bipolar disorder, compared with
healthy controls.35–37 Although these studies primarily suggest an
AKT1 deficiency, a recent study14 found increased AKT1 expression
levels in peripheral blood of antipsychotic-naive schizophrenia
patients. Kumarasinghe et al. (2013) also observed that anti-
psychotic pharmacotherapy could partially compensate for this
upregulation, providing further evidence for a link between AKT1
and dopaminergic transmission.
Although we did not find differences in AKT1 mRNA levels
between SCZ and controls, we found that this gene was
upregulated specifically in BD patients. A previous study in a
Brazilian sample of unmedicated, depressed individuals with
bipolar disorder showed decreased AKT1 expression in the
blood.18 Our finding of increased AKT1 expression in patients on
the opposite pole of the spectrum (in mania) may suggest an
association between AKT1 expression and mood pole.
DICER1 synthesizes DICER, a member of the ribonuclease III
protein family that is involved in the generation of microRNAs
(miRNAs), which regulate gene expression at the posttranscrip-
tional level.38 MiRNAs are 22-nt-long RNAs generated from longer
precursor RNAs. In general, they repress translation, but they can
also acquire other functions after binding to their target RNA.
Notably, many studies implicated miRNAs in the development of
psychotic disorders.39,40
DICER has an important role in the development and function of
the immune41 and central nervous systems.42 DICER1 is upregulated
in the dorsolateral prefrontal cortex42,43 and lymphoblastoid cell
lines44 of schizophrenia cases. In addition, DICER1 single-nucleotide
polymorphisms45 and copy-number variations46 are associated to
schizophrenia. Notably, valproic acid, a mood stabilizer used to treat
bipolar disorder, induces DICER degradation.47
BD and healthy controls
Four genes were upregulated in BD patients compared with
healthy controls (AKT1, DICER1, MBP and NDEL1). AKT1 and DICER1
expression levels were different between BD and SCZ patients,
whereas the expression levels of MBP (myelin basic protein) and
NDEL1 (nuclear distribution of protein nudE-like 1) were similar.
Notably, in our previous findings in a larger cohort of FEP without
bipolar disorder patients we found that MBP and NDEL1 were
upregulated in antipsychotic-naive patients compared with
controls.22 Here we show that these genes are also dysregulated
in FEP with mania.
Myelin-related pathways are involved in the aetiologies of both
schizophrenia and bipolar disorder.48 The MBP gene produces two
families of structurally related proteins from different promoters:
the MBP and the Golli (gene in the oligodendrocyte lineage)
isoforms. In our study, we used an assay that can detect both
types of isoforms (one Golli—NM_001025101, and two classic
MBP isoforms—NM_001025090 and NM_001025092;
Supplementary Table 1). Owing to the higher expression of Golli
isoforms in the immune system,49 we may assume that they
represent the expression detected in our experiments. The
biological function of Golli isoforms involves myelin formation
and maintenance,50 oligodendrocyte proliferation and
migration,51 and calcium homeostasis.52 This specific calcium
pathway is altered in schizophrenia and bipolar disorder53 and is
also affected by antipsychotic medications.54
MBP expression studies in postmortem tissues from different
brain regions revealed an association with psychotic disorders,
suggesting that MBP mRNA and protein levels (of the classic
isoforms) are decreased in patients with schizophrenia 55–57 or
bipolar disorder.58 However, no differences were found in the
Golli-MBP mRNA levels in postmortem dorsolateral prefrontal
cortex samples of schizophrenia patients compared with
controls.59 Notably, MBP expression is affected by antipsychotic
treatment,60,61 and hence, analyzing antipsychotic-naive patients
is essential to attenuate the effects of these medications on gene
expression.
In our study, both antipsychotic-naive SCZ and BD patients
exhibited increased MBP expression levels (most likely Golli
isoforms) compared with healthy controls, suggesting that this
gene might be associated to psychosis per se, as both patient
groups exhibited psychotic symptoms. Indeed, when we analyzed
FEP patients in a larger sample, excluding those with manic
features, MBP was also upregulated compared with healthy
controls22 and to ultra-high risk individuals,23 supporting that
MBP might have a role in psychosis. Moreover, in an independent
report by Kumarasinghe et al. (2013), antipsychotic-naive schizo-
phrenia patients exhibited higher MBP mRNA levels, compared
with controls. After 6 to 8 weeks of risperidone or haloperidol
treatment, the MBP mRNA levels were similar to that of controls.14
However, another study did not reveal significant changes in MBP
in the peripheral blood of first-episode schizophrenia and bipolar
disorder patients.17
NDEL1 is encoded by a gene located at chromosome 17p13.1,
and is robustly expressed in developing and mature neurons in
the brain. It has been suggested to have a role in neuronal
migration during embryogenesis.62 Other well-known functions of
NDEL1 include cytoskeleton organization, cell proliferation and
survival regulation, oligopeptidase activity (potential neuropepti-
dase activity), neuritogenesis, neuronal migration and cell
signaling.63–65 This protein was first discovered due to its
enzyme activity on neuropeptides,66 and second because of its
ability to form complexes with other proteins such as LIS1,
which is encoded by the PAFAH1B1 (platelet-activating factor
acetylhydrolase 1b, regulatory Subunit 1 (45 kDa)) gene that is
mutated in lissencephaly, a rare brain formation disorder.67,68 In
addition, NDEL1 is able to bind DISC1,65 a psychosis-associated
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protein that is the product of a well-known schizophrenia risk
factor gene,69 and is associated with bipolar disorder.70
Gene expression studies conducted in both brain and
peripheral tissues revealed reduced NDEL1 expression levels in
schizophrenia patients.71,72 However, none of these studies have
investigated antipsychotic-naive subjects or patients at the first
stages of psychotic disorders. In a similar analysis, we have
previously reported an upregulation of NDEL1 gene expression in
FEP patients compared with healthy controls.22As we have
included BD patients in the present study, we suggest that NDEL1
expression is also altered in psychotic disorders with manic
features, in the same way as observed in SCZ patients. Moreover, a
subgroup of FEP patients with depression showed lower levels of
NDEL1 expression,20 opposite to our finding in BD, which is also at
the opposite pole of depression. Thus, higher NDEL1 expression
might be characteristic of BD and FEP without depression, while
lower NDEL1 expression levels could be associated to FEP with
depression.
The results of this study need to be replicated in additional
studies and should be interpreted in light of some limitations.
First, the sample size of the groups and particularly the BD patient
group was small, and, hence, it may lack power to identify some
gene expression differences. Second, it was a cross-sectional
study, and the follow-up of these patients would confirm the
diagnosis and may help to find markers for response to treatment.
Third, we did not have a group of patients with mania without
psychotic symptoms. Such a group would help to define which
genes are specifically related to mania. Fourth, we cannot assure if
our findings in whole blood translate to what occurs in the brain.
Considering that whole blood presents a mixture of various
leukocyte subtypes, our gene expression findings may also be
partially confounded by various proportions of leukocyte
subtypes.73 However, an important strength is our focus on
unmedicated patients in the first stages of the disorder.
Consequently, we needed to use a biological material that can
be easily collected, though we acknowledge that peripheral
markers may not necessarily reflect brain pathophysiology.
CONCLUSIONS
To our knowledge, this is the first study that compares gene
expression in antipsychotic-naive FEP of SCZ and FEP with mania
(BD), suggesting potential diagnostic specificities. On the basis of
an integrated model, we propose that MBP and NDEL1 are
upregulated in SCZ and BD patients, who all exhibit psychotic
symptoms. Moreover, two other genes, AKT1 and DICER1, were
upregulated in BD patients only, indicating that these genes could
be related to mania, independently of psychotic symptoms.
Although further validation in a large sample is still needed, our
findings suggest that genes related to neuronal development are
altered in psychotic disorders, and some of them might support
the differential diagnosis between schizophrenia and bipolar
disorder in the near future, which in turn could have an impact on
the treatment of these disorders.
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